Clinical Trials Logo

Radiation Retinopathy clinical trials

View clinical trials related to Radiation Retinopathy.

Filter by:

NCT ID: NCT05844982 Recruiting - Visual Impairment Clinical Trials

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

AL
Start date: November 21, 2023
Phase: Phase 3
Study type: Interventional

This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.

NCT ID: NCT04120636 Active, not recruiting - Epiretinal Membrane Clinical Trials

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Start date: March 5, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the retina, choroid and vitreous.

NCT ID: NCT04120311 Active, not recruiting - Macular Edema Clinical Trials

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Start date: September 1, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.

NCT ID: NCT03238157 Withdrawn - Clinical trials for Radiation Retinopathy

Steroids for Early Treatment of Radiation Retinopathy

Start date: February 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Radiation retinopathy is a known complication of ocular radiation therapy. To date there is no known effective treatment. In addition to their anti-vascular endothelial growth factor (VEGF) properties, corticosteroids decrease the retinal capillary permeability by increasing the activity/density of tight junctions and acute inflammatory effects of radiation in various tissues.

NCT ID: NCT03085784 Active, not recruiting - Clinical trials for Radiation Retinopathy

Intravitreal Aflibercept Injection for Radiation Retinopathy Trial

ARRT
Start date: July 5, 2017
Phase: Phase 2
Study type: Interventional

The ARRT trial will assess the safety and efficacy of 2mg aflibercept for the treatment of radiation retinopathy, including maculopathy and optic neuropathy over 52 weeks.

NCT ID: NCT02222610 Completed - Clinical trials for Radiation Retinopathy

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

RRR
Start date: September 23, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the tolerability and efficacy of ranibizumab treatment administered in subjects with radiation retinopathy

NCT ID: NCT01579760 Completed - Macular Edema Clinical Trials

Intravitreal Aflibercept Injection for Radiation Retinopathy

Start date: November 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety of intravitreal aflibercept injection - in the treatment of macular edema associated with retinopathy secondary to previous radiation therapy.

NCT ID: NCT01471054 Terminated - Macular Edema Clinical Trials

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Start date: April 2014
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex) and compare it with safety and efficacy of intravitreal bevacizumab in eyes with macular edema after plaque radiotherapy of uveal melanoma.

NCT ID: NCT01334879 Completed - Clinical trials for Radiation Retinopathy

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

Start date: May 2011
Phase: Phase 1
Study type: Interventional

This study investigates the use of a high dose anti-VEGF agent for the treatment of radiation retinopathy in those patients who have recalcitrant disease.

NCT ID: NCT00750399 Completed - Choroidal Melanoma Clinical Trials

Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma

Start date: October 2008
Phase: Phase 1
Study type: Interventional

This is a Phase I clinical trial to test the safety and tolerability of intravitreal ranibizumab in the treatment of radiation retinopathy following plaque brachytherapy for patients with choroidal melanoma using the incidence and severity of events criteria. The secondary objective is to assess the efficacy of intravitreal ranibizumab on regression of radiation retinopathy by ophthalmic examination, fundus photography, fluorescein angiography, and optical coherence tomography, as well as visual acuity.